Cancers, Vol. 12, Pages 185: Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Cancers, Vol. 12, Pages 185: Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? Cancers doi: 10.3390/cancers12010185 Authors: Nicoletta Coccaro Luisa Anelli Antonella Zagaria Tommasina Perrone Giorgina Specchia Francesco Albano Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Alonso Arana Maruri Larrucea Mature B-cell non-Hodgkin lymphoma (B-NHL) constitutes a group of heterogeneous malignant lymphoproliferative diseases ranging from indolent to highly aggressive forms. Although the survival after chemo-immunotherapy treatment of mature B-NHL has increased over the last years, many patients relapse or remain refractory due to drug resistance, presenting an unfavorable prognosis. Hence, there is an urgent need to identify new prognostic markers and therapeutic targets. Podocalyxin (PODXL), a sialomucin overexpressed in a variety of tumor cell types and associated with their aggre...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: Although pSS is associated with a higher risk of developing NHL, the risk of NHL appears to have decreased compared with that in previous studies. Our study suggests that the risk of NHL or thyroid cancer with SS is not higher than that reported in previous studies. PMID: 31969226 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in delayed and/or inappropriate treatment, se...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSION: This nationwide population-based study is the first study to report a bidirectional relationship between pSS and NHL. Our findings may suggest being alert for the patients with pSS or NHL who have early signs of the other disease in the clinical care. The underlying mechanisms of the bidirectional relationship merit further investigation. PMID: 31941803 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
Authors: Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I Abstract Introduction: Hepatitis C virus (HCV) is estimated to infect approximately 70 million people worldwide. If left untreated, chronic infection can progress to cirrhosis, liver failure or hepatocellular carcinoma. The advent of new direct-acting antivirals (DAA) has revolutionized patients' chances of treatment and viral elimination. Currently, several DAA options are available on the market.Areas covered: This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combi...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
In this study, CSF samples were acquired from hospitalization patients from the Cancer Center of West China Hospital, Chengdu, China. Comparative proteomic profiling are commonly used to do label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). And in this study the same method was used to characterize the variety of proteins in ENKTL patients and none-ENKTL people.Results: In the aggregate, 421 non-excrescent and functional proteins were identified among the samples. Of these proteins, 45 proteins quantified match the involved criteria. HRG, TIMP-1, SERPINA3, FGA, FGG, TF, FGB, APP, and AGT were significant...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionNHL survivors have high compliance with USPSTF recommendations for cancer screening and immunization. Survivors who are younger or have aggressive lymphomas are less likely to meet the colorectal cancer screening guidelines. Older survivors are more likely to receive influenza vaccination.Implications for Cancer SurvivorsMeasures to further improve preventive care for NHL survivors, especially those younger in age, are necessary.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Abstract Lymphoma is a group of malignant neoplasms of lymphocytes with more than 90 subtypes. It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma. Approximately 82,000 new U.S. patients are diagnosed with lymphoma annually. Any tobacco use and obesity are major modifiable risk factors, with genetic, infectious, and inflammatory etiologies also contributing. Lymphoma typically presents as painless adenopathy, with systemic symptoms of fever, unexplained weight loss, and night sweats occurring in more advanced stages of the disease. An open lymph node biopsy is preferred for diagnosis. The Lug...
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
Lymphomas represent the third most common type of cancer in young people, classified into non-Hodgkin (NHL) or Hodgkin lymphoma. NHL arises when B or T cells, which are involved in the protection, become malignant, growing uncontrollably, "contaminating" the lymphatic system. Characterized by a high degree of malignancy with pathology and immunology of different characteristics. Radiotherapy or chemotherapy are treatments performed for this disease, which may lead to oral manifestations because of its cytotoxicity.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
This study does not go into detail about the extent to which these comorbidities may influence the increased risk of cancer in psoriasis patients. People with severe psoriasis often do not get enough relief with topical therapies (ones applied to the skin), such as topical corticosteroids and vitamin D analogues. They may then be started on medications that target specific immune cells and proteins. Some of these medications increase the risk of infections. Previous studies have found little to no increased risk of cancer in patients receiving these therapies. Other treatments, such as phototherapy (light therapy), are kno...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Skin and Hair Care Source Type: blogs
More News: Cancer | Cancer & Oncology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Rituxan | Study